105 related articles for article (PubMed ID: 12635453)
21. Pioglitazone and rosiglitazone for diabetes.
Drug Ther Bull; 2001 Sep; 39(9):65-8. PubMed ID: 11586802
[TBL] [Abstract][Full Text] [Related]
22. Atherogenic index of plasma [log(triglycerides/HDL-cholesterol)]: theoretical and practical implications.
Dobiásová M
Clin Chem; 2004 Jul; 50(7):1113-5. PubMed ID: 15229146
[No Abstract] [Full Text] [Related]
23. [Value of glitazones in therapy of type 2 diabetes: pro].
Pfohl M
Dtsch Med Wochenschr; 2001 May; 126(20):605. PubMed ID: 11402928
[No Abstract] [Full Text] [Related]
24. Effects of pioglitazone on lipid and lipoprotein metabolism.
Betteridge DJ
Diabetes Obes Metab; 2007 Sep; 9(5):640-7. PubMed ID: 17697057
[TBL] [Abstract][Full Text] [Related]
25. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.
Kendall DM; Rubin CJ; Mohideen P; Ledeine JM; Belder R; Gross J; Norwood P; O'Mahony M; Sall K; Sloan G; Roberts A; Fiedorek FT; DeFronzo RA
Diabetes Care; 2006 May; 29(5):1016-23. PubMed ID: 16644631
[TBL] [Abstract][Full Text] [Related]
26. Pioglitazone-associated fulminant hepatic failure.
Chase MP; Yarze JC
Am J Gastroenterol; 2002 Feb; 97(2):502-3. PubMed ID: 11866308
[No Abstract] [Full Text] [Related]
27. Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats.
Yoshimoto T; Naruse M; Nishikawa M; Naruse K; Tanabe A; Seki T; Imaki T; Demura R; Aikawa E; Demura H
Am J Physiol; 1997 Jun; 272(6 Pt 1):E989-96. PubMed ID: 9227442
[TBL] [Abstract][Full Text] [Related]
28. Using thiazolidinediones: rosiglitazone and pioglitazone in clinical practice.
Peters AL
Am J Manag Care; 2001 Apr; 7(3 Suppl):S87-95; quiz S96-7. PubMed ID: 11310177
[TBL] [Abstract][Full Text] [Related]
29. [Pioglitazone].
Kobayashi M; Iwata M; Hiratani K
Nihon Rinsho; 2002 Sep; 60 Suppl 9():429-37. PubMed ID: 12387029
[No Abstract] [Full Text] [Related]
30. Long-term lipid effects of pioglitazone by baseline anti-hyperglycemia medication therapy and statin use from the PROactive experience (PROactive 14).
Spanheimer R; Betteridge DJ; Tan MH; Ferrannini E; Charbonnel B;
Am J Cardiol; 2009 Jul; 104(2):234-9. PubMed ID: 19576353
[TBL] [Abstract][Full Text] [Related]
31. Glitazones and the potential improvement of lipid profiles in diabetes patients at high risk for cardiovascular disease.
Nass CM; Blumenthal RS
Am J Manag Care; 2000 Dec; 6(24 Suppl):S1247-56; quiz S1257-8. PubMed ID: 11142005
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial.
Schernthaner G; Matthews DR; Charbonnel B; Hanefeld M; Brunetti P;
J Clin Endocrinol Metab; 2004 Dec; 89(12):6068-76. PubMed ID: 15579760
[TBL] [Abstract][Full Text] [Related]
33. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
Derosa G; D'Angelo A; Salvadeo SA; Ferrari I; Gravina A; Fogari E; Maffioli P; Cicero AF
Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
[TBL] [Abstract][Full Text] [Related]
34. LDL cholesterol and troglitazone therapy.
Howard BV; Howard WJ
Diabetes Care; 1998 Dec; 21(12):2201-3. PubMed ID: 9839127
[No Abstract] [Full Text] [Related]
35. Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) study.
Nicholls SJ; Tuzcu EM; Wolski K; Bayturan O; Lavoie A; Uno K; Kupfer S; Perez A; Nesto R; Nissen SE
J Am Coll Cardiol; 2011 Jan; 57(2):153-9. PubMed ID: 21211686
[TBL] [Abstract][Full Text] [Related]
36. Improvement of asthma after administration of pioglitazone.
Hashimoto Y; Nakahara K
Diabetes Care; 2002 Feb; 25(2):401. PubMed ID: 11815521
[No Abstract] [Full Text] [Related]
37. [Rosiglitazone: clinical data].
Blickle JF
Ann Endocrinol (Paris); 2002 Apr; 63(2 Pt 2):1S27-33. PubMed ID: 12037505
[No Abstract] [Full Text] [Related]
38. Severe decrease in serum HDL-cholesterol during combination therapy of bezafibrate and pioglitazone.
Senba H; Kawano M; Kawakami M
J Atheroscler Thromb; 2006 Oct; 13(5):263-4. PubMed ID: 17146155
[No Abstract] [Full Text] [Related]
39. Effect of thiazolidinediones on lipid profile.
Madan P
CMAJ; 2005 Aug; 173(4):344; author reply 344-5. PubMed ID: 16103495
[No Abstract] [Full Text] [Related]
40. [Oral therapy in type 2 diabetes. Critical evaluation of glitazones].
Lotz N
MMW Fortschr Med; 2002 Jan; 144(3-4):48-50. PubMed ID: 11862793
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
